Skill Checkup: A 59-Year-Old Man With Dyspnea on Exertion and a Nonproductive Cough

Zab Mosenifar, MD


April 15, 2022

CT is currently considered the best predictor of progression; previous decline in forced vital capacity is not a reliable indicator of future decline.

Diagnostic biomarkers for fibrotic lung disease have not been validated; however, increased circulating fibrocytes have been suggested in patients with IPF, though data regarding vascular endothelial growth factor are contradictory. Asthma is not associated with disease progression.

Functional parameters used to monitor and evaluate disease progression include the percentage value on the predicted forced vital capacity, the diffusion capacity of the lung for carbon monoxide, and 6-minute walk distance data. Worsening dyspnea is also a primary indicator of disease progression, as are acute exacerbations.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.